Our team recently demonstrated that a model of IC-FcγR binding accurately captured and could predict in vitro binding across various IgG isotypes.16 Further, it could accurately predict antibody-elicited tumor cell killing in mice across antibodies of varied isotypes, glycosylation statuses, and FcγR knockouts.16 Directly quantifying and predicting cell clearance makes it possible to accurately anticipate and optimize for antibody-mediated therapeutic effects. The gene discussed is FCGR2A; the disease is neoplasm.